

## Anemia and Heart Failure: Addressing Functional Iron Deficiency

by Amanda Peffer, Pharm.D.

### References

1. Klutstein MW, Tzivoni D. Anaemia and heart failure: aetiology and treatment. *Nephrol Dial Transplant* 2005;20(suppl 7):vii7-vii10.
2. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). *J Am Coll Cardiol* 2003;41:1933-1939.
3. Eckardt K. Managing a fateful alliance: anaemia and cardiovascular outcomes. *Nephrol Dial Transplant* 2005;20(suppl 6):vi16-vi20.
4. Wexler D, Silverberg D, Blum M, et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. *Nephrol Dial Transplant* 2005;20(suppl 7):vii11-vii15.
5. Iaina A, Silverberg DW, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. *Nat Clin Pract Cardiovasc Med* 2005;2(2):95-100.
6. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. *Nephrol Dial Transplant* 2003;18(suppl 2):ii7-ii12.
7. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. *Cardiovasc Res* 2003;59(3):538-548.
8. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006;113:1424-1433.
9. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. *J Am Coll Cardiol* 2002;40:27-33.
10. Opasich C, Cazzola M, Sceisi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. *Eur Heart J* 2005;26:2232-2237.
11. Iyengar S, Abraham WT. Anemia in chronic heart failure: can EPO reduce deaths? *Cleve Clin J Med* 2005;72(11):1027-1032.
12. Johnson JA, Parker RB, Patterson JH. Heart Failure. In: Dipiro JT, Talbert RL, Yee GC, (eds). *Pharmacotherapy: a pathophysiologic approach*. Stamford: Appleton & Lange; 2002:185-218.
13. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005 10;352(10):1011-1023.
14. Henry DH, Bowers P, Romano MT, et al. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. *Arch Intern Med* 2004;164(3):262-276.
15. Katz SD, Mancini D, Androne AS, et al. Treatment of anemia in patients with chronic heart failure. *J Card Fail* 2004;10(suppl 1):S13-16.

(Continued on page 2)

---

A University of Washington Drug Information Center publication  
Distributed monthly by authority of the Pharmacy and Therapeutics Committee  
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.  
Department of Pharmacy Services / School of Pharmacy

---

Copyright © 2006 by the University of Washington  
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>  
No material may be reproduced in whole or in part without written permission from the editor.

**References**

(continued)

16. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. *J Am Coll Cardiol* 2000;35:1737-1744.
17. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. *J Am Coll Cardiol* 2001;37:1775-1780.
18. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. *Nephrol Dial Transplant* 2003;18:141-146.
19. Mancini DM, Katz SD, Lang CC. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. *Circulation* 2003;107(2):294-299.
20. Cleland JG, Sullivan JT, Ball S. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia. A pharmacokinetic and pharmacodynamic investigation. *J Cardiovasc Pharmacol* 2005;46:155-161.
21. Cavill I. Erythropoiesis and iron. *Best Pract Res Clin Haematol* 2002;15(2):339-409.
22. National Kidney Foundation Dialysis Outcomes Quality Initiative: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure, 2000. *Am J Kidney Dis* 2001;37(suppl 1):S182-S238.
23. Eschbach JW. Iron requirements in erythropoietin therapy. *Best Pract Res Clin Haematol* 2005;18(2):347-61.
24. Cook JD. Diagnosis and management of iron-deficiency anaemia. *Best Pract Res Clin Haematol* 2005;18(2):319-332.
25. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. *Clin Chem* 2003;49(10):1573-1578.
26. Waters HM, Seal LH. A systematic approach to the assessment of erythropoiesis. *Clin Lab Haem* 2001;23:271-283.
27. Klasco RK (Ed). DRUGDEX<sup>®</sup> System [Internet version]. Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: <http://www.thomsonhc.com> [Last accessed 4/26/06].
28. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. *Sem Dial* 2006;19(2):146-151.
29. Richardson D. Clinical factors influencing sensitivity and response to epoetin. *Nephrol Dial Transplant* 2002;17(suppl 1):53-59.